Iadecola C, Smith EE, Anrather J, Gu C, Mishra A, Misra S, et al. The neurovasculome: key roles in brain health and cognitive impairment: a scientific statement from the American Heart Association/American Stroke Association. Stroke. 2023;54:e251.
Fisher RA, Miners JS, Love S. Pathological changes within the cerebral vasculature in Alzheimer’s disease: new perspectives. Brain Pathol. 2022;32(6):e13061.
Tarasoff-Conway JM, Carare RO, Osorio RS, Glodzik L, Butler T, Fieremans E, et al. Clearance systems in the brain—implications for Alzheimer disease. Nat Rev Neurol. 2015;11(8):457–70.
Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–62.
Siegel GJ, Agranoff BW, Albers RW, et al., editors. Basic Neurochemistry: Molecular, Cellular and Medical Aspects. 6th edition. Philadelphia: Lippincott-Raven; 1999.
Gottesman RF, Albert MS, Alonso A, Coker LH, Coresh J, Davis SM, et al. Associations between midlife vascular risk factors and 25-year incident dementia in the Atherosclerosis Risk in Communities (ARIC) Cohort. JAMA Neurol. 2017;74(10):1246–54.
Mosconi L, Walters M, Sterling J, Quinn C, McHugh P, Andrews RE, et al. Lifestyle and vascular risk effects on MRI-based biomarkers of Alzheimer’s disease: a cross-sectional study of middle-aged adults from the broader New York City area. BMJ Open. 2018;8(3): e019362.
Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data. Lancet Neurol. 2014;13(8):788–94.
Vu TT, Zhao L, Liu L, Schiman C, Lloyd-Jones DM, Daviglus ML, et al. Favorable cardiovascular health at young and middle ages and dementia in older age-The CHA study. J Am Heart Assoc. 2019;8(1): e009730.
Tan ECK, Qiu C, Liang Y, Wang R, Bell JS, Fastbom J, et al. Antihypertensive medication regimen intensity and incident dementia in an older population. J Am Med Dir Assoc. 2018;19(7):577–83.
Solomon A, Kivipelto M, Soininen H. Prevention of Alzheimer’s disease: moving backward through the lifespan. J Alzheimer’s Dis : JAD. 2013;33(Suppl 1):S465–9.
Sweeney MD, Montagne A, Sagare AP, Nation DA, Schneider LS, Chui HC, et al. Vascular dysfunction-The disregarded partner of Alzheimer’s disease. Alzheimer’s Dementia. 2019;15(1):158–67.
Hassler O. Vascular changes in senile brains. A Micro-Angiograph Study Acta Neuropathol. 1965;5(1):40–53.
Bell MA, Ball MJ. Morphometric comparison of hippocampal microvasculature in ageing and demented people: diameters and densities. Acta Neuropathol. 1981;53(4):299–318.
Fischer VW, Siddiqi A, Yusufaly Y. Altered angioarchitecture in selected areas of brains with Alzheimer’s disease. Acta Neuropathol. 1990;79(6):672–9.
Kalaria RN, Hedera P. Differential degeneration of the cerebral microvasculature in Alzheimer’s disease. NeuroReport. 1995;6(3):477–80.
Zipser BD, Johanson CE, Gonzalez L, Berzin TM, Tavares R, Hulette CM, et al. Microvascular injury and blood-brain barrier leakage in Alzheimer’s disease. Neurobiol Aging. 2007;28(7):977–86.
Challa VR, Thore CR, Moody DM, Anstrom JA, Brown WR. Increase of white matter string vessels in Alzheimer’s disease. J Alzheimer’s Dis: JAD. 2004;6(4):379–83.
Kuhn J, Sharman T. Cerebral Amyloid Angiopathy. [Updated 2023 Jun 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. https://www.ncbi.nlm.nih.gov/books/NBK556105/.
Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M, et al. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer’s coordinating centre. Brain : A J Neurol. 2013;136(Pt 9):2697–706.
Arvanitakis Z, Capuano AW, Leurgans SE, Bennett DA, Schneider JA. Relation of cerebral vessel disease to Alzheimer’s disease dementia and cognitive function in elderly people: a cross-sectional study. Lancet Neurol. 2016;15(9):934–43.
Biffi A, Greenberg SM. Cerebral amyloid angiopathy: a systematic review. J Clin Neurol (Seoul, Korea). 2011;7(1):1–9.
Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, et al. Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier. J Clin Investig. 2000;106(12):1489–99.
Lam FC, Liu R, Lu P, Shapiro AB, Renoir JM, Sharom FJ, et al. β-Amyloid efflux mediated by p-glycoprotein. J Neurochem. 2001;76(4):1121–8.
Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, et al. Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular Aβ clearance. Neuron. 2009;64(5):632–44.
Prior R, Wihl G, Urmoneit B. Apolipoprotein E, Smooth Muscle Cells and the Pathogenesis of Cerebral Amyloid Angiopathy: the Potential Role of Impaired Cerebrovascular Abeta Clearance. Annals of the New York Academy of Sciences. 2000;903(1 Vascular fact):180–6.
Hawkes CA, Jayakody N, Johnston DA, Bechmann I, Carare RO. Failure of perivascular drainage of β-amyloid in cerebral amyloid angiopathy. Brain Pathol. 2014;24(4):396–403.
2020 Alzheimer’s disease facts and figures. Alzheimers Dement. 2020;16(3):391–460. https://doi.org/10.1002/alz.12068.
van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2022;388(1):9–21.
Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. Donanemab in early Alzheimer’s disease. N Engl J Med. 2021;384(18):1691–704.
Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512–27.
Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two randomized phase 3 studies of Aducanumab in early Alzheimer’s disease. J Prev Alzheimer’s Dis. 2022;9:197.
Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 2012;69(2):198–207.
Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM, et al. Consequence of Abeta immunization on the vasculature of human Alzheimer’s disease brain. Brain : A J Neurol. 2008;131(Pt 12):3299–310.
Eng JA, Frosch MP, Choi K, Rebeck GW, Greenberg SM. Clinical manifestations of cerebral amyloid angiopathy-related inflammation. Ann Neurol. 2004;55(2):250–6.
Scolding NJ, Joseph F, Kirby PA, Mazanti I, Gray F, Mikol J, et al. Aβ-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy. Brain. 2005;128(3):500–15.
Antolini L, DiFrancesco JC, Zedde M, Basso G, Arighi A, Shima A, et al. Spontaneous ARIA-like events in cerebral amyloid angiopathy-related inflammation. A Multicenter Prospect Longitudinal Cohort Study. 2021;97(18):e1809–22.
Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s association research roundtable workgroup. Alzheimers Dement. 2011;7(4):367–85.
Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science (New York, NY). 1993;261(5123):921–3.
Castellano JM, Deane R, Gottesdiener AJ, Verghese PB, Stewart FR, West T, et al. Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis. Proc Natl Acad Sci U S A. 2012;109(38):15502–7.
Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest. 2008;118(12):4002–13.
Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549(7673):523–7.
Montagne A, Nation DA, Sagare AP, Barisano G, Sweeney MD, Chakhoyan A, et al. APOE4 leads to blood–brain barrier dysfunction predicting cognitive decline. Nature. 2020;581(7806):71–6.
Barisano G, Kisler K, Wilkinson B, Nikolakopoulou AM, Sagare AP, Wang Y, et al. A “multi-omics” analysis of blood–brain barrier and synaptic dysfunction in APOE4 mice. J Exp Med. 2022;219(11):20221137.
Sheline YI, Morris JC, Snyder AZ, Price JL, Yan Z, D’Angelo G, et al. APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Aβ42. J Neurosci. 2010;30(50):17035–40.
Lynch JR, Tang W, Wang H, Vitek MP, Bennett ER, Sullivan PM, et al. APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response*. J Biol Chem. 2003;278(49):48529–33.
Vitek MP, Brown CM, Colton CA. APOE genotype-specific differences in the innate immune response. Neurobiol Aging. 2009;30(9):1350–60.
Sacre SM, Stannard AK, Owen JS. Apolipoprotein E (apoE) isoforms differentially induce nitric oxide production in endothelial cells. FEBS Lett. 2003;540(1):181–7.
Ulrich V, Konaniah ES, Herz J, Gerard RD, Jung E, Yuhanna IS, et al. Genetic variants of ApoE and ApoER2 differentially modulate endothelial function. Proc Natl Acad Sci. 2014;111(37):13493–8.
Wu L, Zhang X, Zhao L. Human ApoE isoforms differentially modulate brain glucose and ketone body metabolism: implications for Alzheimer’s disease risk reduction and early intervention. J Neurosci. 2018;38(30):6665–81.
Bouchareychas L, Raffai RL. Apolipoprotein E and atherosclerosis: from lipoprotein metabolism to MicroRNA control of inflammation. J Cardiovasc Dev Dis. 2018;5(2):30.
Linton MF, Gish R, Hubl ST, Bütler E, Esquivel C, Bry WI, et al. Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J Clin Invest. 1991;88(1):270–81.
Liu M, Kuhel DG, Shen L, Hui DY, Woods SC. Apolipoprotein E does not cross the blood-cerebrospinal fluid barrier, as revealed by an improved technique for sampling CSF from mice. Am J Physiol Regul Integr Comp Physiol. 2012;303(9):R903–8.
Bonaterra-Pastra A, Fernández-De-Retana S, Rivas-Urbina A, Puig N, Benítez S, Pancorbo O, et al. Comparison of plasma lipoprotein composition and function in cerebral amyloid angiopathy and Alzheimer’s disease. Biomedicines. 2021;9(1):72.
Van Valkenburgh J, Meuret C, Martinez AE, Kodancha V, Solomon V, Chen K, et al. Understanding the exchange of systemic HDL particles into the brain and vascular cells has diagnostic and therapeutic implications for neurodegenerative diseases. Front Physiol. 2021;12: 700847.
Wang T, Wang X, Yao Y, Zhao C, Yang C, Han Y, et al. Association of plasma apolipoproteins and levels of inflammation-related factors with different stages of Alzheimer’s disease: a cross-sectional study. BMJ Open. 2022;12(4): e054347.
Giannisis A, Al-Grety A, Carlsson H, Patra K, Twohig D, Sando SB, et al. Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer’s disease. Alzheimer’s Res Ther. 2022;14(1):115.
Liu C-C, Zhao J, Fu Y, Inoue Y, Ren Y, Chen Y, et al. Peripheral apoE4 enhances Alzheimer’s pathology and impairs cognition by compromising cerebrovascular function. Nat Neurosci. 2022;25(8):1020–33.
Diffenderfer MR, Schaefer EJ. The composition and metabolism of large and small LDL. Curr Opin Lipidol. 2014;25(3):221–6.
Krauss RM. Lipoprotein subfractions and cardiovascular disease risk. Curr Opin Lipidol. 2010;21(4):305–11.
Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res. 1982;23(1):97–104.
Griffin BA, Caslake MJ, Yip B, Tait GW, Packard CJ, Shepherd J. Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by density gradient ultracentrifugation. Atherosclerosis. 1990;83(1):59–67.
Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. Eur Heart J. 2017;38(32):2459–72.
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2019;41(1):111–88.
Mundi S, Massaro M, Scoditti E, Carluccio MA, van Hinsbergh VWM, Iruela-Arispe ML, et al. Endothelial permeability, LDL deposition, and cardiovascular risk factors-a review. Cardiovasc Res. 2018;114(1):35–52.
Borén J, Olin K, Lee I, Chait A, Wight TN, Innerarity TL. Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding. J Clin Invest. 1998;101(12):2658–64.
Vink H, Constantinescu AA, Spaan JA. Oxidized lipoproteins degrade the endothelial surface layer : implications for platelet-endothelial cell adhesion. Circulation. 2000;101(13):1500–2.
Li W, Wang C, Zhang D, Zeng K, Xiao S, Chen F, et al. Azilsartan ameliorates ox-LDL-induced endothelial dysfunction via promoting the expression of KLF2. Aging (Albany NY). 2021;13(9):12996–3005.
Ghaffari S, Naderi Nabi F, Sugiyama MG, Lee WL. Estrogen inhibits LDL (Low-Density Lipoprotein) transcytosis by human coronary artery endothelial cells via GPER (G-Protein-Coupled Estrogen Receptor) and SR-BI (Scavenger Receptor Class B Type 1). Arterioscler Thromb Vasc Biol. 2018;38(10):2283–94.
Sáiz-Vazquez O, Puente-Martínez A, Ubillos-Landa S, Pacheco-Bonrostro J, Santabárbara J. Cholesterol and Alzheimer’s disease risk: a meta-meta-analysis. Brain Sci. 2020;10(6):386.
Iwagami M, Qizilbash N, Gregson J, Douglas I, Johnson M, Pearce N, et al. Blood cholesterol and risk of dementia in more than 1·8 million people over two decades: a retrospective cohort study. Lancet Healthy Longev. 2021;2(8):e498–506.
Wee J, Sukudom S, Bhat S, Marklund M, Peiris NJ, Hoyos CM, et al. The relationship between midlife dyslipidemia and lifetime incidence of dementia: A systematic review and meta-analysis of cohort studies. Alzheimer’s Dementia: Diagn, Assess Dis Monitor. 2023;15(1): e12395.
Mineo C, Shaul PW. Novel biological functions of high-density lipoprotein cholesterol. Circ Res. 2012;111(8):1079–90.
Michell DL, Vickers KC. Lipoprotein carriers of microRNAs. Biochimica et Biophysica Acta (BBA) – Mol Cell Biol Lipids. 2016;1861(12):2069–74.
Davidson WS, Shah AS, Sexmith H, Gordon SM. The HDL proteome watch: compilation of studies leads to new insights on HDL function. Biochim Biophys Acta Mol Cell Biol Lipids. 2022;1867(2): 159072.
Boyce G, Button E, Soo S, Wellington C. The pleiotropic vasoprotective functions of high density lipoproteins (HDL). J Biomed Res. 2017;32(3):164–82.
Shah AS, Tan L, Long JL, Davidson WS. Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond. J Lipid Res. 2013;54(10):2575–85.
Toth PP, Barter PJ, Rosenson RS, Boden WE, Chapman MJ, Cuchel M, et al. High-density lipoproteins: a consensus statement from the national lipid association. J Clin Lipidol. 2013;7(5):484–525.
Chiesa ST, Charakida M. High-density lipoprotein function and dysfunction in health and disease. Cardiovasc Drugs Ther. 2019;33(2):207–19.
El Khoudary SR, Ceponiene I, Samargandy S, Stein JH, Li D, Tattersall MC, et al. HDL (High-Density Lipoprotein) metrics and atherosclerotic risk in women. Arterioscler Thromb Vasc Biol. 2018;38(9):2236–44.
Furtado JD, Yamamoto R, Melchior JT, Andraski AB, Gamez-Guerrero M, Mulcahy P, et al. Distinct proteomic signatures in 16 HDL (High-Density Lipoprotein) subspecies. Arterioscler Thromb Vasc Biol. 2018;38(12):2827–42.
Morton AM, Koch M, Mendivil CO, Furtado JD, Tjønneland A, Overvad K, et al. Apolipoproteins E and CIII interact to regulate HDL metabolism and coronary heart disease risk. JCI Insight. 2018;3(4):e98045.
Button EB, Robert J, Caffrey TM, Fan J, Zhao W, Wellington CL. HDL from an Alzheimer’s disease perspective. Curr Opin Lipidol. 2019;30(3):224–34.
Soppert J, Lehrke M, Marx N, Jankowski J, Noels H. Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting. Adv Drug Deliv Rev. 2020;159:4–33.
Kontush A. HDL and Reverse Remnant-Cholesterol Transport (RRT): relevance to cardiovascular disease. Trends Mol Med. 2020;26(12):1086–100.
Zuliani G, Cavalieri M, Galvani M, Volpato S, Cherubini A, Bandinelli S, et al. Relationship between low levels of high-density lipoprotein cholesterol and dementia in the elderly. The InChianti study. J Gerontol A Biol Sci Med Sci. 2010;65(5):559–64.
Shih YH, Tsai KJ, Lee CW, Shiesh SC, Chen WT, Pai MC, et al. Apolipoprotein C-III is an amyloid-β-binding protein and an early marker for Alzheimer’s disease. J Alzheimers Dis. 2014;41(3):855–65.
Merched A, Xia Y, Visvikis S, Serot JM, Siest G. Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer’s disease. Neurobiol Aging. 2000;21(1):27–30.
Reed B, Villeneuve S, Mack W, Decarli C, Chui HC, Jagust W. Associations between serum cholesterol levels and cerebral amyloidosis. JAMA Neurol. 2014;71(2):195.
Saczynski JS, White L, Peila RL, Rodriguez BL, Launer LJ. The relation between apolipoprotein A-I and dementia: the Honolulu-Asia aging study. Am J Epidemiol. 2007;165(9):985–92.
Armstrong NM, An Y, Beason-Held L, Doshi J, Erus G, Ferrucci L, et al. Predictors of neurodegeneration differ between cognitively normal and subsequently impaired older adults. Neurobiol Aging. 2019;75:178–86.
Tan ZS, Seshadri S, Beiser A, Wilson PWF, Kiel DP, Tocco M, et al. Plasma total cholesterol level as a risk factor for Alzheimer disease. Arch Intern Med. 2003;163(9):1053.
Formiga F, Ferrer A, Chivite D, Pinto X, Cuerpo S, Pujol R. Serum high-density lipoprotein cholesterol levels, their relationship with baseline functional and cognitive status, and their utility in predicting mortality in nonagenarians. Geriatr Gerontol Int. 2011;11(3):358–64.
Marcum ZA, Walker R, Bobb JF, Sin MK, Gray SL, Bowen JD, et al. Serum cholesterol and incident Alzheimer’s disease: findings from the adult changes in thought study. J Am Geriatr Soc. 2018;66(12):2344–52.
Li G, Shofer JB, Kukull WA, Peskind ER, Tsuang DW, Breitner JC, et al. Serum cholesterol and risk of Alzheimer disease: a community-based cohort study. Neurology. 2005;65(7):1045–50.
Mielke MM, Xue QL, Zhou J, Chaves PH, Fried LP, Carlson MC. Baseline serum cholesterol is selectively associated with motor speed and not rates of cognitive decline: the women’s health and aging study II. J Gerontol A Biol Sci Med Sci. 2008;63(6):619–24.
Yaffe K, Barrett-Connor E, Lin F, Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol. 2002;59(3):378.
Bates KA, Sohrabi HR, Rainey-Smith SR, Weinborn M, Bucks RS, Rodrigues M, et al. Serum high-density lipoprotein is associated with better cognitive function in a cross-sectional study of aging women. Int J Neurosci. 2017;127(3):243–52.
Wei S, Gao L, Jiang Y, Shang S, Chen C, Dang L, et al. The Apolipoprotein E ε4 Allele-dependent relationship between serum lipid levels and cognitive function: a population-based cross-sectional study. Front Aging Neurosci. 2020;12:44.
Luo J, Thomassen JQ, Bellenguez C, Grenier-Boley B, De Rojas I, Castillo A, et al. Genetic associations between modifiable risk factors and Alzheimer disease. JAMA Netw Open. 2023;6(5): e2313734.
Heeren J, Grewal T, Laatsch A, Rottke D, Rinninger F, Enrich C, et al. Recycling of apoprotein E is associated with cholesterol efflux and high density lipoprotein internalization. J Biol Chem. 2003;278(16):14370–8.
Annema W, Dikkers A, de Boer JF, Gautier T, Rensen PC, Rader DJ, et al. ApoE promotes hepatic selective uptake but not RCT due to increased ABCA1-mediated cholesterol efflux to plasma. J Lipid Res. 2012;53(5):929–40.
Qi Y, Liu J, Wang W, Wang M, Zhao F, Sun J, et al. Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk: a community-based cohort study. J Clin Lipidol. 2018;12(1):89–98.e2.
Koch M, DeKosky ST, Goodman M, Sun J, Furtado JD, Fitzpatrick AL, et al. High density lipoprotein and its apolipoprotein-defined subspecies and risk of dementia. J Lipid Res. 2020;61(3):445–54.
Koch M, DeKosky ST, Goodman M, Sun J, Furtado JD, Fitzpatrick AL, et al. Association of Apolipoprotein E in Lipoprotein subspecies with risk of dementia. JAMA Netw Open. 2020;3(7): e209250.
Kothapalli D, Liu SL, Bae YH, Monslow J, Xu T, Hawthorne EA, et al. Cardiovascular protection by ApoE and ApoE-HDL linked to suppression of ECM gene expression and arterial stiffening. Cell Rep. 2012;2(5):1259–71.
Robert J, Button EB, Yuen B, Gilmour M, Kang K, Bahrabadi A, et al. Clearance of beta-amyloid is facilitated by apolipoprotein E and circulating high-density lipoproteins in bioengineered human vessels. Elife. 2017;6:2e9595.
Robert J, Button EB, Martin EM, McAlary L, Gidden Z, Gilmour M, et al. Cerebrovascular amyloid Angiopathy in bioengineered vessels is reduced by high-density lipoprotein particles enriched in Apolipoprotein E. Mol Neurodegenerat. 2020;15(1):23.
Robert J, Weilinger NL, Cao L-P, Cataldi S, Button EB, Stukas S, et al. An in vitro bioengineered model of the human arterial neurovascular unit to study neurodegenerative diseases. Mol Neurodegenerat. 2020;15(1):70.
Blanchard JW, Bula M, Davila-Velderrain J, Akay LA, Zhu L, Frank A, et al. Reconstruction of the human blood–brain barrier in vitro reveals a pathogenic mechanism of APOE4 in pericytes. Nat Med. 2020;26(6):952–63.
Schaefer EJ, Lamon-Fava S, Cohn SD, Schaefer MM, Ordovas JM, Castelli WP, et al. Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham offspring study. J Lipid Res. 1994;35(5):779–92.
Jensen J, Nilas L, Christiansen C. Influence of menopause on serum lipids and lipoproteins. Maturitas. 1990;12(4):321–31.
Bonithon-Kopp C, Scarabin PY, Darne B, Malmejac A, Guize L. Menopause-related changes in lipoproteins and some other cardiovascular risk factors. Int J Epidemiol. 1990;19(1):42–8.
Cífková R, Krajčoviechová A. Dyslipidemia and cardiovascular disease in women. Curr Cardiol Rep. 2015;17(7):609.
Hunt NB, Emmens JE, Irawati S, de Vos S, Bos JHJ, Wilffert B, et al. Sex disparities in the effect of statins on lipid parameters: The pharmlines initiative. Medicine (Baltimore). 2022;101(2): e28394.
Olmastroni E, Boccalari MT, Tragni E, Rea F, Merlino L, Corrao G, et al. Sex-differences in factors and outcomes associated with adherence to statin therapy in primary care: need for customisation strategies. Pharmacol Res. 2020;155: 104514.
Paquette M, Faubert S, Saint-Pierre N, Baass A, Bernard S. Sex differences in LDL-C response to PCSK9 inhibitors: a real world experience. J Clin Lipidol. 2023;17(1):142–9.
Drayna D, Jarnagin AS, McLean J, Henzel W, Kohr W, Fielding C, et al. Cloning and sequencing of human cholesteryl ester transfer protein cDNA. Nature. 1987;327(6123):632–4.
Hesler CB, Swenson TL, Tall AR. Purification and characterization of a human plasma cholesteryl ester transfer protein. J Biol Chem. 1987;262(5):2275–82.
Barter PJ, Hopkins GJ, Calvert GD. Transfers and exchanges of esterified cholesterol between plasma lipoproteins. Biochem J. 1982;208(1):1–7.
Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, et al. Safety of Anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363(25):2406–15.
Ha YC, Barter PJ. Differences in plasma cholesteryl ester transfer activity in sixteen vertebrate species. Comp Biochem Physiol B. 1982;71(2):265–9.
Sjöstedt E, Zhong W, Fagerberg L, Karlsson M, Mitsios N, Adori C, et al. An atlas of the protein-coding genes in the human, pig, and mouse brain. Science. 2020;367(6482):eaay5947.
Human Protein Atlas. Available from: proteinatlas.org.
Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581(7809):434–43.
Ference BA, Kastelein JJP, Ginsberg HN, Chapman MJ, Nicholls SJ, Ray KK, et al. Association of genetic variants related to CETP inhibitors and statins with Lipoprotein levels and cardiovascular risk. JAMA. 2017;318(10):947–56.
Papp AC, Pinsonneault JK, Wang D, Newman LC, Gong Y, Johnson JA, et al. Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk. PLoS ONE. 2012;7(3): e31930.
Suhy A, Hartmann K, Papp AC, Wang D, Sadee W. Regulation of cholesteryl ester transfer protein expression by upstream polymorphisms. Pharmacogenet Genomics. 2015;25(8):394–401.
Piko P, Jenei T, Kosa Z, Sandor J, Kovacs N, Seres I, et al. Association of CETP gene Polymorphisms and Haplotypes with cardiovascular risk. Int J Mol Sci. 2023;24(12):10281.
Semaev S, Shakhtshneider E, Shcherbakova L, Orlov P, Ivanoshchuk D, Malyutina S, et al. Association of common variants APOE, CETP, and the 9p21.3 of and the chromosomal region with the risk of myocardial infarction a prospective study. Int J Mol Sci. 2023;24(13):10908.
Wang Q, Zhou SB, Wang LJ, Lei MM, Wang Y, Miao C, et al. Seven functional polymorphisms in the CETP gene and myocardial infarction risk: a meta-analysis and meta-regression. PLoS ONE. 2014;9(2): e88118.
Thompson A, Di Angelantonio E, Sarwar N, Erqou S, Saleheen D, Dullaart RPF, et al. Association of Cholesteryl Ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA. 2008;299(23):2777–88.
Johnson EC, Border R, Melroy-Greif WE, de Leeuw CA, Ehringer MA, Keller MC. No evidence that Schizophrenia candidate genes are more associated with Schizophrenia than noncandidate genes. Biol Psychiat. 2017;82(10):702–8.
Boekholdt SM, Thompson JF. Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. J Lipid Res. 2003;44(6):1080–93.
Sundermann EE, Wang C, Katz M, Zimmerman ME, Derby CA, Hall CB, et al. Cholesteryl ester transfer protein genotype modifies the effect of apolipoprotein ε4 on memory decline in older adults. Neurobiol Aging. 2016;41:200.e7-.e12.
Lythgoe C, Perkes A, Peterson M, Schmutz C, Leary M, Ebbert MT, et al. Population-based analysis of cholesteryl ester transfer protein identifies association between I405V and cognitive decline: the Cache county study. Neurobiol Aging. 2015;36(1):547.e1–3.
Chen JJ, Li YM, Zou WY, Fu JL. Relationships between CETP genetic polymorphisms and Alzheimer’s disease risk: a meta-analysis. DNA Cell Biol. 2014;33(11):807–15.
Izaks GJ, van der Knaap AM, Gansevoort RT, Navis G, Slaets JP, Dullaart RP. Cholesteryl Ester Transfer Protein (CETP) genotype and cognitive function in persons aged 35 years or older. Neurobiol Aging. 2012;33(8):1851.e7–16.
Murphy EA, Roddey JC, McEvoy LK, Holland D, Hagler DJ Jr, Dale AM, et al. CETP polymorphisms associate with brain structure, atrophy rate, and Alzheimer’s disease risk in an APOE-dependent manner. Brain Imaging Behav. 2012;6(1):16–26.
Warstadt NM, Dennis EL, Jahanshad N, Kohannim O, Nir TM, McMahon KL, et al. Serum cholesterol and variant in cholesterol-related gene CETP predict white matter microstructure. Neurobiol Aging. 2014;35(11):2504–13.
Barzilai N, Atzmon G, Derby CA, Bauman JM, Lipton RB. A genotype of exceptional longevity is associated with preservation of cognitive function. Neurology. 2006;67(12):2170–5.
Sanders AE, Wang C, Katz M, Derby CA, Barzilai N, Ozelius L, et al. Association of a functional polymorphism in the cholesteryl ester transfer protein (CETP) gene with memory decline and incidence of dementia. JAMA. 2010;303(2):150–8.
Yu L, Shulman JM, Chibnik L, Leurgans S, Schneider JA, De Jager PL, et al. The CETP I405V polymorphism is associated with an increased risk of Alzheimer’s disease. Aging Cell. 2012;11(2):228–33.
Arias-Vásquez A, Isaacs A, Aulchenko YS, Hofman A, Oostra BA, Breteler M, et al. The cholesteryl ester transfer protein (CETP) gene and the risk of Alzheimer’s disease. Neurogenetics. 2007;8(3):189–93.
Georgakis MK, Malik R, Anderson CD, Parhofer KG, Hopewell JC, Dichgans M. Genetic determinants of blood lipids and cerebral small vessel disease: role of high-density lipoprotein cholesterol. Brain. 2020;143(2):597–610.
Marotti KR, Castle CK, Boyle TP, Lin AH, Murray RW, Melchior GW. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature. 1993;364(6432):73–5.
Plump AS, Masucci-Magoulas L, Bruce C, Bisgaier CL, Breslow JL, Tall AR. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler Thromb Vasc Biol. 1999;19(4):1105–10.
Westerterp M, van der Hoogt CC, de Haan W, Offerman EH, Dallinga-Thie GM, Jukema JW, et al. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice. Arterioscler Thromb Vasc Biol. 2006;26(11):2552–9.
Herrera VL, Makrides SC, Xie HX, Adari H, Krauss RM, Ryan US, et al. Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival in Dahl salt-sensitive hypertensive rats transgenic for human cholesteryl ester transfer protein. Nat Med. 1999;5(12):1383–9.
Oestereich F, Yousefpour N, Yang E, Phénix J, Nezhad ZS, Nitu A, et al. The cholesteryl ester transfer protein (CETP) raises cholesterol levels in the brain. J Lipid Res. 2022;63(9): 100260.
Benoit ME, Tenner AJ. Complement protein C1q-mediated neuroprotection is correlated with regulation of neuronal gene and microRNA expression. J Neurosci. 2011;31(9):3459–69.
Silverman SM, Kim B-J, Howell GR, Miller J, John SWM, Wordinger RJ, et al. C1q propagates microglial activation and neurodegeneration in the visual axis following retinal ischemia/reperfusion injury. Mol Neurodegen. 2016;11(1):24.
Tooyama I, Sato H, Yasuhara O, Kimura H, Konishi Y, Shen Y, et al. Correlation of the expression level of C1q mRNA and the number of C1q-positive plaques in the Alzheimer disease temporal cortex. Analysis of mrna and its protein using adjacent or nearby sections. Dement Geriatr Cogn Disord. 2001;12(4):237–42.
Reichwald J, Danner S, Wiederhold KH, Staufenbiel M. Expression of complement system components during aging and amyloid deposition in APP transgenic mice. J Neuroinflammation. 2009;6:35.
Stephan AH, Madison DV, Mateos JM, Fraser DA, Lovelett EA, Coutellier L, et al. A dramatic increase of C1q protein in the CNS during normal aging. J Neurosci. 2013;33(33):13460–74.
Dejanovic B, Wu T, Tsai M-C, Graykowski D, Gandham VD, Rose CM, et al. Complement C1q-dependent excitatory and inhibitory synapse elimination by astrocytes and microglia in Alzheimer’s disease mouse models. Nature Aging. 2022;2(9):837–50.
Krance SH, Wu C-Y, Zou Y, Mao H, Toufighi S, He X, et al. The complement cascade in Alzheimer’s disease: a systematic review and meta-analysis. Mol Psychiatry. 2021;26(10):5532–41.
Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109–22.
Suico JG, Friedrich S, Krueger KA, Zhang W. Evacetrapib at a supratherapeutic steady state concentration does not prolong QT in a thorough QT/QTc study in healthy participants. J Cardiovasc Pharmacol Ther. 2014;19(3):283–9.
Krishna R, Anderson MS, Bergman AJ, Jin B, Fallon M, Cote J, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet. 2007;370(9603):1907–14.
Hovingh GK, Kastelein JJ, van Deventer SJ, Round P, Ford J, Saleheen D, et al. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2015;386(9992):452–60.
Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367(22):2089–99.
Tall AR, Rader DJ. Trials and tribulations of CETP inhibitors. Circ Res. 2018;122(1):106–12.
Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, et al. Effects of Anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377(13):1217–27.
Late-Breaking Science Abstracts and Featured Science Abstracts From the American Heart Association’s Scientific Sessions 2019 and Late-Breaking Abstracts in Resuscitation Science From the Resuscitation Science Symposium 2019. Circulation. 2019;140(25):e965–e1011.
Phénix J, Côté J, Dieme D, Recinto SJ, Oestereich F, Efrem S, et al. CETP inhibitor evacetrapib enters mouse brain tissue. Front Pharmacol. 2023;14:1171937.
Nicholls SJ, Ditmarsch M, Kastelein JJ, Rigby SP, Kling D, Curcio DL, et al. Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial. Nat Med. 2022;28(8):1672–8.
Cerneckis J, Bu G, Shi Y. Pushing the boundaries of brain organoids to study Alzheimer’s disease. Trends Mol Med. 2023;29(8):659–72.
Helman AM, Murphy MP. Vascular cognitive impairment: modeling a critical neurologic disease in vitro and in vivo. Biochimica et Biophysica Acta Mol Basis Dis. 2016;1862(5):975–82.
Smith EN, Chen W, Kähönen M, Kettunen J, Lehtimäki T, Peltonen L, et al. Longitudinal genome-wide association of cardiovascular disease risk factors in the bogalusa heart study. PLoS Genet. 2010;6(9): e1001094.
Iwanicka J, Iwanicki T, Niemiec P, Balcerzyk A, Krauze J, Górczyńska-Kosiorz S, et al. Relationship between CETP gene polymorphisms with coronary artery disease in Polish population. Mol Biol Rep. 2018;45(6):1929–35.
Peloso GM, Lee SJ, Sims R, Lee SJ, Naj AC, Bellenguez C, et al. Genetically elevated high-density lipoprotein cholesterol through the cholesteryl ester transfer protein gene does not associate with risk of Alzheimer’s disease. Alzheimer’s Dementia: Diagn Assesst Dis Monitor. 2018;10(1):595–8.
Webb TR, Erdmann J, Stirrups KE, Stitziel NO, Masca NGD, Jansen H, et al. Systematic evaluation of pleiotropy identifies 6 further loci associated with coronary artery disease. J Am Coll Cardiol. 2017;69(7):823–36.
Johannsen TH, Frikke-Schmidt R, Schou J, Nordestgaard BG, Tybjærg-Hansen A. Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects. J Am Coll Cardiol. 2012;60(20):2041–8.
Qureischie H, Heun R, Lütjohann D, Popp J, Jessen F, Ledschbor-Frahnert C, et al. CETP polymorphisms influence cholesterol metabolism but not Alzheimer’s disease risk. Brain Res. 2008;1232:1–6.
Rodríguez E, Mateo I, Infante J, Llorca J, Berciano J, Combarros O. Cholesteryl ester transfer protein (CETP) polymorphism modifies the Alzheimer’s disease risk associated with APOE ε4 allele. J Neurol. 2006;253(2):181–5.
Ridker PM, Paré G, Parker AN, Zee RY, Miletich JP, Chasman DI. Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 initially healthy women from the women’s genome health study. Circ Cardiovasc Genet. 2009;2(1):26–33.
Xiao Z, Wang J, Chen W, Wang P, Zeng H, Chen W. Association studies of several cholesterol-related genes (ABCA1, CETP and LIPC) with serum lipids and risk of Alzheimer’s disease. Lipids Health Dis. 2012;11(1):163.
Li Q, Huang P, He Q-C, Lin Q-Z, Wu J, Yin R-X. Association between the CETP polymorphisms and the risk of Alzheimer’s disease, carotid atherosclerosis, longevity, and the efficacy of statin therapy. Neurobiol Aging. 2014;35(6):1513.e13-.e23.
Yehya A, Irshaid Y, Saleh AA. Cholesteryl ester transfer protein rs1532624 gene polymorphism is associated with reduced response to statin therapy. Curr Mol Pharmacol. 2013;6(3):156–62.
Adams LA, Marsh JA, Ayonrinde OT, Olynyk JK, Ang WQ, Beilin LJ, et al. Cholesteryl ester transfer protein gene polymorphisms increase the risk of fatty liver in females independent of adiposity. J Gastroenterol Hepatol. 2012;27(9):1520–7.
Cyrus C, Vatte C, Al-Nafie A, Chathoth S, Al-Ali R, Al-Shehri A, et al. The impact of common polymorphisms in CETP and ABCA1 genes with the risk of coronary artery disease in Saudi Arabians. Human Genomics. 2016;10(1):8.
Peloso GM, Demissie S, Collins D, Mirel DB, Gabriel SB, Cupples LA, et al. Common genetic variation in multiple metabolic pathways influences susceptibility to low HDL-cholesterol and coronary heart disease. J Lipid Res. 2010;51(12):3524–32.
Add Comment